#USA #Rockville #cancer therapies #Series B Funding #OncoC4

OncoC4 Secures Nearly $50 Million in Series B Financing

OncoC4, a biotechnology company dedicated to fighting cancer and neurodegenerative diseases, has recently announced the successful closing of its Series B financing round that totals nearly $50 million. The latest funding was led by GBA Fund, alongside contributions from the company's co-founders and various existing investors such as HM Capital, 3E Bioventures Capital, and Kaitai Capital.

Founded in 2020 by distinguished immunologists and entrepreneurs Dr. Yang Liu and Dr. Pan Zheng, OncoC4 has made significant strides in the field of immuno-oncology and translational medicine. The company has developed a rich pipeline of innovative therapies, many of which have potential to be first-in-class or best-in-class.

According to Dr. Yang Liu, Co-Founder and CEO of OncoC4, the Series B round progressed swiftly, demonstrating the investors' confidence in the company's vision and capabilities. He emphasized the commitment to advancing the clinical development of their key pipeline while also expanding their business development activities. The goal is clear: to deliver groundbreaking therapies to patients on a global scale.

The funding from the Series B round will primarily be allocated to expedite the clinical development of OncoC4's promising pipeline programs. This includes leveraging their proprietary technologies to bring new biologics for cancer treatment into clinical trials more effectively. OncoC4 is poised to establish itself as a leader in the biotechnology sector, focusing on targeted therapies for patients suffering from a variety of cancers and neurodegenerative disorders.

OncoC4 is based in Rockville, Maryland, and plays an active role in the discovery and development of novel treatments that address significant unmet medical needs. The company's pipeline includes assets targeting both novel and validated targets across oncology and immunology.

With the support of its investors and an unwavering commitment to innovation and patient care, OncoC4 is set to significantly impact the landscape of cancer therapies. Their ongoing projects and future initiatives aim to redefine treatment options and improve patient outcomes in the field of oncology.

Dr. Liu’s leadership and the collaborative efforts of the founding team will be vital as OncoC4 transitions to the next phase of development, bringing hope to patients around the world who are battling life-threatening diseases.

For additional information, investors are encouraged to reach out to Ryan Cui, the Executive Director of Investor Relations at OncoC4. The company remains focused on its mission to deliver safe, effective therapies to those in need.

In conclusion, as OncoC4 embarks on this new phase of funding and development, it promises to drive forward with its mission to advance innovative solutions in the fight against cancer, demonstrating the importance of collaboration between investors, researchers, and healthcare professionals.